{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T21:55:12Z","timestamp":1790546112593,"version":"4.1.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2011,3,31]],"date-time":"2011-03-31T00:00:00Z","timestamp":1301529600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clin Exp Metastasis"],"published-print":{"date-parts":[[2011,6]]},"DOI":"10.1007\/s10585-011-9386-8","type":"journal-article","created":{"date-parts":[[2011,3,30]],"date-time":"2011-03-30T07:28:20Z","timestamp":1301470100000},"page":"479-491","source":"Crossref","is-referenced-by-count":47,"title":["Impact of combined HDAC and mTOR inhibition on adhesion, migration and invasion of prostate cancer cells"],"prefix":"10.1007","volume":"28","author":[{"given":"Steffen","family":"Wedel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lukasz","family":"Hudak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens-Michael","family":"Seibel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jasmina","family":"Makarevi\u0107","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Juengel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Igor","family":"Tsaur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Wiesner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Axel","family":"Haferkamp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roman A.","family":"Blaheta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2011,3,31]]},"reference":[{"key":"9386_CR1","doi-asserted-by":"crossref","first-page":"71","DOI":"10.3322\/CA.2007.0010","volume":"58","author":"A Jemal","year":"2008","unstructured":"Jemal A, Siegel R, Ward E et al (2008) Cancer statistics, 2008. CA Cancer J Clin 58:71\u201396","journal-title":"CA Cancer J Clin"},{"key":"9386_CR2","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1038\/ncpuro0145","volume":"2","author":"JF Ward","year":"2005","unstructured":"Ward JF, Moul JW (2005) Rising prostate-specific antigen after primary prostate cancer therapy. Nat Clin Pract Urol 2:174\u2013182","journal-title":"Nat Clin Pract Urol"},{"key":"9386_CR3","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/S0094-0143(05)70163-4","volume":"28","author":"M Han","year":"2001","unstructured":"Han M, Partin AW, Pound CR et al (2001) Long-term biochemical disease-free and cancer-specific survival following anatomic radical retropubic prostatectomy. The 15-year Johns Hopkins experience. Urol Clin North Am 28:555\u2013565","journal-title":"Urol Clin North Am"},{"key":"9386_CR4","first-page":"62","volume":"1","author":"L Wang","year":"2009","unstructured":"Wang L, Zou X, Berger AD et al (2009) Increased expression of histone deacetylaces (HDACs) and inhibition of prostate cancer growth and invasion by HDAC inhibitor SAHA. Am J Transl Res 1:62\u201371","journal-title":"Am J Transl Res"},{"key":"9386_CR5","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1038\/sj.bjc.6604199","volume":"98","author":"W Weichert","year":"2008","unstructured":"Weichert W, R\u00f6ske A, Gekeler V et al (2008) Histone deacetylases 1, 2 and 3 are highly expressed in prostate cancer and HDAC2 expression is associated with shorter PSA relapse time after radical prostatectomy. Br J Cancer 98:604\u2013610","journal-title":"Br J Cancer"},{"key":"9386_CR6","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1002\/pros.20022","volume":"59","author":"K Halkidou","year":"2004","unstructured":"Halkidou K, Gaughan L, Cook S et al (2004) Upregulation and nuclear recruitment of HDAC1 in hormone refractory prostate cancer. Prostate 59:177\u2013189","journal-title":"Prostate"},{"key":"9386_CR7","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1002\/pros.20410","volume":"66","author":"CL Kremer","year":"2006","unstructured":"Kremer CL, Klein RR, Mendelson J et al (2006) Expression of mTOR signaling pathway markers in prostate cancer progression. Prostate 66:1203\u20131212","journal-title":"Prostate"},{"key":"9386_CR8","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1111\/j.1464-410X.2009.08538.x","volume":"104","author":"B Dai","year":"2009","unstructured":"Dai B, Kong YY, Ye DW et al (2009) Activation of the mammalian target of rapamycin signalling pathway in prostate cancer and its association with patient clinicopathological characteristics. BJU Int 104:1009\u20131016","journal-title":"BJU Int"},{"key":"9386_CR9","doi-asserted-by":"crossref","first-page":"3860","DOI":"10.1158\/1078-0432.CCR-07-0091","volume":"13","author":"R Bedolla","year":"2007","unstructured":"Bedolla R, Prihoda TJ, Kreisberg JI et al (2007) Determining risk of biochemical recurrence in prostate cancer by immunohistochemical detection of PTEN expression and Akt activation. Clin Cancer Res 13:3860\u20133867","journal-title":"Clin Cancer Res"},{"key":"9386_CR10","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1111\/j.1464-410X.2007.07014.x","volume":"100","author":"Y Shimizu","year":"2007","unstructured":"Shimizu Y, Segawa T, Inoue T et al (2007) Increased Akt and phosphorylated Akt expression are associated with malignant biological features of prostate cancer in Japanese men. BJU Int 100:685\u2013690","journal-title":"BJU Int"},{"key":"9386_CR11","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1002\/pros.20708","volume":"68","author":"A Angelucci","year":"2008","unstructured":"Angelucci A, Muzi P, Cristiano L et al (2008) Neuroendocrine transdifferentiation induced by VPA is mediated by PPARgamma activation and confers resistance to antiblastic therapy in prostate carcinoma. Prostate 68:588\u2013598","journal-title":"Prostate"},{"key":"9386_CR12","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1002\/pros.20587","volume":"67","author":"S Shabbeer","year":"2007","unstructured":"Shabbeer S, Kortenhorst MS, Kachhap S et al (2007) Multiple molecular pathways explain the anti-proliferative effect of valproic acid on prostate cancer cells in vitro and in vivo. Prostate 67:1099\u20131110","journal-title":"Prostate"},{"key":"9386_CR13","doi-asserted-by":"crossref","first-page":"7237","DOI":"10.1158\/0008-5472.CAN-05-0487","volume":"66","author":"Q Xia","year":"2006","unstructured":"Xia Q, Sung J, Chowdhury W et al (2006) Chronic administration of valproic acid inhibits prostate cancer cell growth in vitro and in vivo. Cancer Res 66:7237\u20137244","journal-title":"Cancer Res"},{"key":"9386_CR14","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1002\/pros.20752","volume":"68","author":"TM Morgan","year":"2008","unstructured":"Morgan TM, Pitts TE, Gross TS et al (2008) RAD001 (Everolimus) inhibits growth of prostate cancer in the bone and the inhibitory effects are increased by combination with docetaxel and zoledronic acid. Prostate 68:861\u2013871","journal-title":"Prostate"},{"key":"9386_CR15","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1158\/1535-7163.MCT-07-0581","volume":"7","author":"A Schayowitz","year":"2008","unstructured":"Schayowitz A, Sabnis G, Njar VC et al (2008) Synergistic effect of a novel antiandrogen, VN\/124-1, and signal transduction inhibitors in prostate cancer progression to hormone independence in vitro. Mol Cancer Ther 7:121\u2013132","journal-title":"Mol Cancer Ther"},{"key":"9386_CR16","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.mvr.2007.04.002","volume":"74","author":"M Iiizumi","year":"2007","unstructured":"Iiizumi M, Mohinta S, Bandyopadhyay S et al (2007) Tumor-endothelial cell interactions: therapeutic potential. Microvasc Res 74:114\u2013120","journal-title":"Microvasc Res"},{"key":"9386_CR17","doi-asserted-by":"crossref","first-page":"8648","DOI":"10.1158\/0008-5472.CAN-06-1544","volume":"66","author":"CL Hall","year":"2006","unstructured":"Hall CL, Dai J, van Golen KL et al (2006) Type I collagen receptor (alpha 2 beta 1) signaling promotes the growth of human prostate cancer cells within the bone. Cancer Res 66:8648\u20138654","journal-title":"Cancer Res"},{"key":"9386_CR18","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.3892\/ijo_00000302","volume":"34","author":"S Slambrouck Van","year":"2009","unstructured":"Van Slambrouck S, Jenkins AR, Romero AE et al (2009) Reorganization of the integrin alpha2 subunit controls cell adhesion and cancer cell invasion in prostate cancer. Int J Oncol 34:1717\u20131726","journal-title":"Int J Oncol"},{"key":"9386_CR19","first-page":"2129","volume":"25","author":"JM Liu","year":"2005","unstructured":"Liu JM, Bignon J, Haroun-Bouhedja F et al (2005) Inhibitory effect of fucoidan on the adhesion of adenocarcinoma cells to fibronectin. Anticancer Res 25:2129\u20132133","journal-title":"Anticancer Res"},{"key":"9386_CR20","doi-asserted-by":"crossref","unstructured":"Chao WT, Kunz J (2009) Focal adhesion disassembly requires clathrin-dependent endocytosis of integrins. FEBS Lett 583:1337\u20131343","DOI":"10.1016\/j.febslet.2009.03.037"},{"key":"9386_CR21","first-page":"347","volume":"18","author":"A Oertl","year":"2006","unstructured":"Oertl A, Relja B, Makarevic J et al (2006) Altered expression of beta1 integrins in renal carcinoma cell lines exposed to the differentiation inducer valproic acid. Int J Mol Med 18:347\u2013354","journal-title":"Int J Mol Med"},{"key":"9386_CR22","doi-asserted-by":"crossref","first-page":"2774","DOI":"10.1002\/ijc.23885","volume":"123","author":"M Bj\u00f6rkman","year":"2008","unstructured":"Bj\u00f6rkman M, Iljin K, Halonen P et al (2008) Defining the molecular action of HDAC inhibitors and synergism with androgen deprivation in ERG-positive prostate cancer. Int J Cancer 123:2774\u20132781","journal-title":"Int J Cancer"},{"key":"9386_CR23","first-page":"837","volume":"12","author":"O Nagakawa","year":"2004","unstructured":"Nagakawa O, Akashi T, Hayakawa Y et al (2004) Differential expression of integrin subunits in DU-145\/AR prostate cancer cells. Oncol Rep 12:837\u2013841","journal-title":"Oncol Rep"},{"key":"9386_CR24","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1158\/0008-5472.CAN-08-2216","volume":"69","author":"DS Welsbie","year":"2009","unstructured":"Welsbie DS, Xu J, Chen Y et al (2009) Histone deacetylases are required for androgen receptor function in hormone-sensitive and castrate-resistant prostate cancer. Cancer Res 69:958\u2013966","journal-title":"Cancer Res"},{"key":"9386_CR25","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1002\/jcb.10665","volume":"91","author":"JK Slack-Davis","year":"2004","unstructured":"Slack-Davis JK, Parsons JT (2004) Emerging views of integrin signaling: implications for prostate cancer. J Cell Biochem 91:41\u201346","journal-title":"J Cell Biochem"},{"key":"9386_CR26","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1038\/sj.neo.7900223","volume":"4","author":"M Schmelz","year":"2002","unstructured":"Schmelz M, Cress AE, Scott KM et al (2002) Different phenotypes in human prostate cancer: alpha6 or alpha3 integrin in cell-extracellular adhesion sites. Neoplasia 4:243\u2013254","journal-title":"Neoplasia"},{"key":"9386_CR27","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1002\/pros.20799","volume":"68","author":"TH Lai","year":"2008","unstructured":"Lai TH, Fong YC, Fu WM et al (2008) Osteoblasts-derived BMP-2 enhances the motility of prostate cancer cells via activation of integrins. Prostate 68:1341\u20131353","journal-title":"Prostate"},{"key":"9386_CR28","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1002\/pros.20168","volume":"63","author":"X Wang","year":"2005","unstructured":"Wang X, Ferreira AM (2005) Shao Q et al. (2005) Beta3 integrins facilitate matrix interactions during transendothelial migration of PC3 prostate tumor cells. Prostate 63:65\u201380","journal-title":"Prostate"},{"key":"9386_CR29","doi-asserted-by":"crossref","first-page":"42214","DOI":"10.1074\/jbc.M303428200","volume":"278","author":"S Balasubramanian","year":"2003","unstructured":"Balasubramanian S, Kuppuswamy D (2003) RGD-containing peptides activate S6K1 through beta3 integrin in adult cardiac muscle cells. J Biol Chem 278:42214\u201342224","journal-title":"J Biol Chem"},{"key":"9386_CR30","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1002\/pros.20566","volume":"67","author":"M Priulla","year":"2007","unstructured":"Priulla M, Calastretti A, Bruno P et al (2007) Preferential chemosensitization of PTEN-mutated prostate cells by silencing the Akt kinase. Prostate 67:782\u2013789","journal-title":"Prostate"},{"key":"9386_CR31","doi-asserted-by":"crossref","first-page":"3589","DOI":"10.1158\/1078-0432.CCR-07-4306","volume":"14","author":"HM Verheul","year":"2008","unstructured":"Verheul HM, Salumbides B, Van Erp K et al (2008) Combination strategy targeting the hypoxia inducible factor-1 alpha with mammalian target of rapamycin and histone deacetylase inhibitors. Clin Cancer Res 14:3589\u20133597","journal-title":"Clin Cancer Res"},{"key":"9386_CR32","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1158\/1078-0432.CCR-09-1385","volume":"16","author":"D Mahalingam","year":"2010","unstructured":"Mahalingam D, Medina EC, Esquivel JA 2nd et al (2010) Vorinostat enhances the activity of temsirolimus in renal cell carcinoma through suppression of survivin levels. Clin Cancer Res 16:141\u2013153","journal-title":"Clin Cancer Res"},{"key":"9386_CR33","doi-asserted-by":"crossref","first-page":"2621","DOI":"10.1038\/onc.2009.129","volume":"28","author":"L Taliaferro-Smith","year":"2009","unstructured":"Taliaferro-Smith L, Nagalingam A, Zhong D et al (2009) LKB1 is required for adiponectin-mediated modulation of AMPK-S6K axis and inhibition of migration and invasion of breast cancer cells. Oncogene 28:2621\u20132633","journal-title":"Oncogene"},{"key":"9386_CR34","doi-asserted-by":"crossref","first-page":"38879","DOI":"10.1074\/jbc.M505733200","volume":"280","author":"CS Chen","year":"2005","unstructured":"Chen CS, Weng SC, Tseng PH et al (2005) Histone acetylation-independent effect of histone deacetylase inhibitors on Akt through the reshuffling of protein phosphatase 1 complexes. J Biol Chem 280:38879\u201338887","journal-title":"J Biol Chem"},{"key":"9386_CR35","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1038\/sj.bjc.6604726","volume":"99","author":"E Ridolfi","year":"2008","unstructured":"Ridolfi E, Matteucci E, Maroni P et al (2008) Inhibitory effect of HGF on invasiveness of aggressive MDA-MB231 breast carcinoma cells, and role of HDACs. Br J Cancer 99:1623\u20131634","journal-title":"Br J Cancer"},{"key":"9386_CR36","doi-asserted-by":"crossref","first-page":"3312","DOI":"10.1016\/j.yexcr.2009.09.022","volume":"315","author":"MC Lydolph","year":"2009","unstructured":"Lydolph MC, Morgan-Fisher M, H\u00f8ye AM et al (2009) Alpha9beta1 integrin in melanoma cells can signal different adhesion states for migration and anchorage. Exp Cell Res 315:3312\u20133324","journal-title":"Exp Cell Res"},{"key":"9386_CR37","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.1158\/0008-5472.CAN-07-1246","volume":"68","author":"M Lakshman","year":"2008","unstructured":"Lakshman M, Xu L, Ananthanarayanan V et al (2008) Dietary genistein inhibits metastasis of human prostate cancer in mice. Cancer Res 68:2024\u20132032","journal-title":"Cancer Res"},{"key":"9386_CR38","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1038\/onc.2008.390","volume":"28","author":"MR Russell","year":"2009","unstructured":"Russell MR, Jamieson WL, Dolloff NG, Fatatis A (2009) The alpha-receptor for platelet-derived growth factor as a target for antibody-mediated inhibition of skeletal metastases from prostate cancer cells. Oncogene 28:412\u2013421","journal-title":"Oncogene"}],"container-title":["Clinical & Experimental Metastasis"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10585-011-9386-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10585-011-9386-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10585-011-9386-8","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,9]],"date-time":"2019-06-09T10:47:20Z","timestamp":1560077240000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10585-011-9386-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,3,31]]},"references-count":38,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2011,6]]}},"alternative-id":["9386"],"URL":"https:\/\/doi.org\/10.1007\/s10585-011-9386-8","relation":{},"ISSN":["0262-0898","1573-7276"],"issn-type":[{"value":"0262-0898","type":"print"},{"value":"1573-7276","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,3,31]]}}}